Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: A phase 2 study of the department of defense prostate cancer clinical trials consortium

Andrea L. Harzstark, Jonathan E. Rosenberg, Vivian K. Weinberg, Jeremy Sharib, Charles J. Ryan, David C. Smith, Lance C. Pagliaro, Tomasz M. Beer, Glenn Liu, Eric J. Small

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Fingerprint Dive into the research topics of 'Ixabepilone, mitoxantrone, and prednisone for metastatic castration-resistant prostate cancer after docetaxel-based therapy: A phase 2 study of the department of defense prostate cancer clinical trials consortium'. Together they form a unique fingerprint.

Medicine & Life Sciences